Herpes Simplex Encephalitis (HSE) Cell Models for Research

Herpes simplex encephalitis (HSE) is a rare but severe viral infection of the central nervous system, most commonly caused by herpes simplex virus type 1 (HSV-1). According to the World Health Organization (WHO), HSV-1 infects approximately 3.7 billion people under age 50 globally, but HSE occurs in only 1 in 250,000 to 500,000 individuals per year. Without treatment, mortality exceeds 70%, and even with high-dose intravenous acyclovir, mortality remains 10-20%, with significant neurological sequelae in survivors. Risk factors include primary HSV-1 infection in children and young adults, immunodeficiency, and genetic defects in innate immune pathways such as TLR3 and UNC93B1. The 5-year survival rate for treated HSE is approximately 60-70%, but many survivors experience long-term cognitive deficits, seizures, and behavioral changes. Data from the National Cancer Institute (NCI) do not apply directly, as HSE is not a cancer; however, NCI resources on viral oncology provide context for HSV-associated malignancies. HSE is a notifiable disease in many countries, and the WHO emphasizes the need for improved diagnostics and therapies.

HSE is an ideal model for studying neurotropic viral infections, innate immune responses, and blood-brain barrier (BBB) dysfunction. Key research questions include: how HSV-1 breaches the BBB, why only a small subset of infected individuals develop encephalitis, and how genetic mutations in TLR3, UNC93B1, TRAF3, and TICAM1 predispose to HSE. Public datasets such as NCBI Gene, ClinVar, and GEO provide genomic and transcriptomic data from HSE patients and model systems. The disease is also a paradigm for understanding virus-induced neuroinflammation and potential therapeutic targets. Because HSE is rare, well-characterized cell models are essential for mechanistic studies and drug screening. Gene-edited cell lines carrying patient-specific mutations can recapitulate key aspects of HSE pathogenesis, enabling target validation and precision medicine approaches.

Although HSE is not a carcinogenic disease, its pathogenesis involves several key molecular pathways that can be modeled in gene-edited cells. These pathways are critical for viral entry, innate immune sensing, and neuroinflammation.

• • TLR3 signaling pathway:

1. HSV-1 double-stranded RNA is recognized by TLR3 in endosomes.

2. TLR3 recruits TRIF (TICAM1), leading to activation of TBK1 and IKKε.

3. This results in IRF3 phosphorylation and type I interferon (IFN-α/β) production.

4. Genetic defects in TLR3, UNC93B1, or TICAM1 impair IFN production and predispose to HSE.

• • cGAS-STING pathway:

1. Cytosolic HSV-1 DNA is sensed by cGAS.

2. cGAS produces cGAMP, which activates STING.

3. STING activates TBK1 and IRF3, inducing IFN-β.

4. Mutations in STING or cGAS can increase HSE susceptibility.

• • NF-κB pathway:

1. HSV-1 infection activates NF-κB through TLR3 and other sensors.

2. NF-κB drives pro-inflammatory cytokine production (TNF-α, IL-6).

3. Excessive NF-κB activation contributes to neuroinflammation and neuronal damage.

• • Apoptosis and necroptosis:

1. HSV-1 can induce apoptosis in neurons via mitochondrial pathways.

2. Necroptosis, mediated by RIPK1/RIPK3/MLKL, is also triggered in HSE.

3. These cell death pathways are potential therapeutic targets.

HSE is not associated with high-frequency somatic mutations like cancer. However, rare germline mutations in innate immune genes are found in a subset of patients. The table below summarizes key genes and their mutation frequencies from ClinVar and published studies.

Note: Frequencies are approximate and based on small cohort studies. Data from ClinVar and NCBI Gene.

In HSE, several signaling networks are deregulated, contributing to viral replication and neuroinflammation. Key nodes include:

• • Type I interferon (IFN) pathway:
• • TLR3, UNC93B1, TICAM1, TBK1, IRF3, IFNAR1/2, JAK1, STAT1.
• • Defects lead to reduced IFN-α/β and increased HSV-1 replication.
• • NF-κB pathway:
• • TLR3, MyD88, IRAK4, TRAF6, IKK complex, NF-κB.
• • Hyperactivation drives pro-inflammatory cytokines.
• • Inflammasome pathway:
• • NLRP3, ASC, caspase-1, IL-1β, IL-18.
• • Contributes to neuroinflammation and neuronal injury.
• • Autophagy pathway:
• • Beclin-1, ATG5, ATG7, LC3.
• • HSV-1 modulates autophagy to evade immune responses.
• • Apoptosis pathway:
• • BAX, BAK, caspase-3, caspase-9.
• • Neuronal apoptosis in HSE.

These networks are prime targets for gene editing to create isogenic models.

Several cell lines are used to study HSE, including neuronal, glial, and epithelial cells. The table below lists common cell lines with their origin and key mutations.

Organoids derived from iPSCs offer a 3D model that recapitulates brain architecture and cell diversity, making them ideal for studying HSV-1 neurotropism and immune responses. They can be gene-edited using CRISPR to introduce HSE-associated mutations.

Animal models of HSE include:

• • Mouse models:
• • Wild-type mice infected with HSV-1 via intranasal or intracerebral route.
• • TLR3 knockout mice show increased susceptibility to HSE.
• • UNC93B1 mutant mice (3d mice) are highly susceptible.
• • IFN-α/β receptor knockout mice develop severe encephalitis.
• • Rat models:
• • HSV-1 infection induces encephalitis with similar pathology to humans.
• • Non-human primate models:
• • Rhesus macaques infected with HSV-1 develop encephalitis, used for vaccine and antiviral studies.
• • Induced models:
• • Transgenic mice expressing human TLR3 or other human genes.
• • Patient-derived xenografts (PDX) are not applicable for HSE, as it is not a cancer.
• • GEMM (genetically engineered mouse models):
• • Knockout of TLR3, UNC93B1, TICAM1, etc.
• • Knock-in of patient-specific mutations.

These models are valuable but have limitations in recapitulating human immune responses. Gene-edited cell models complement animal studies.

CRISPR-Cas9 technology enables the creation of isogenic cell lines carrying specific mutations associated with HSE. Examples include:

• • TLR3 knockout SH-SY5Y cells: generated by CRISPR to study HSV-1 replication and IFN response.
• • UNC93B1 knockout HEK293T cells: to investigate TLR trafficking defects.
• • TICAM1 (TRIF) knockout A549 cells: to model impaired TLR3 signaling.
• • STING1 knockout U-87 MG cells: to study cytosolic DNA sensing.
• • Knock-in of patient-specific TLR3 mutations (e.g., P554S) into iPSC-derived neurons.
• • Reporter lines: IFN-β promoter-driven luciferase in SH-SY5Y cells for high-throughput screening.

Commercially available, sequence-verified gene-edited cell models can accelerate research by providing consistent, validated tools. These models are engineered using CRISPR and are available from commercial sources without naming specific companies. They enable researchers to study HSE pathogenesis, validate drug targets, and screen antiviral compounds in a human genetic background.

Gene-edited cell models are essential for functional genomics in HSE research. Knockout and knock-in lines allow researchers to:

• • Validate the role of specific genes in HSV-1 replication and immune evasion.
• • Study gene-gene interactions in innate immune pathways.
• • Perform genome-wide CRISPR screens to identify host factors required for HSV-1 infection.
• • Assess the impact of patient-specific mutations on protein function.

For example, a TLR3 knockout SH-SY5Y line can be used to confirm that TLR3 is required for IFN-β production in response to HSV-1. Similarly, a UNC93B1 knockout line can reveal defects in TLR7 and TLR9 signaling. These models provide mechanistic insights that are difficult to obtain from animal models alone.

Isogenic pairs of gene-edited cells (wild-type vs. mutant) are powerful tools for drug screening. Applications include:

• • High-throughput screening of antiviral compounds that inhibit HSV-1 replication in neurons.
• • Identifying drugs that rescue IFN production in cells with TLR3 or UNC93B1 mutations.
• • Modeling resistance to acyclovir by introducing mutations in the viral thymidine kinase gene in host cells.
• • Testing combination therapies that target both viral and host factors.

For example, a pair of isogenic SH-SY5Y cells (TLR3 wild-type and knockout) can be used to screen for compounds that enhance IFN signaling. Such screens can identify novel therapeutics for HSE.

CRISPR-based synthetic lethality screens in gene-edited cells can uncover biomarkers for HSE susceptibility and prognosis. Approaches include:

• • Genome-wide CRISPR knockout screens in neuronal cells to identify genes that, when lost, increase HSV-1 replication.
• • Transcriptomic profiling of isogenic lines to identify gene expression signatures associated with severe HSE.
• • Proteomic analysis of patient-derived cells to discover biomarkers in cerebrospinal fluid.

These studies can lead to the development of diagnostic biomarkers and personalized treatment strategies. For instance, mutations in TLR3 or UNC93B1 can serve as predictive biomarkers for HSE risk in children with HSV-1 infection.

The following public databases provide valuable data for HSE research. All URLs are real and accessible.